Neuromuscular DiseasesNeuromuscular DiseasesНервно-мышечные болезни2222-87212413-0443Publishing House ABV Press12410.17650/2222-8721-2015-5-3-50-61ORIGINAL REPORTSОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯPositive experience of the usage of Rituximab in management of refractory myasthenia gravis in RussiaРоссийский опыт успешного применения ритуксимаба при рефрактерных формах миастении грависShcherbakovaN. I.ЩербаковаН. И.Russian Federationshnata@inbox.ruSuponevaN. A.СупоневаН. А.Russian FederationShvedkovV. V.ШведковВ. В.Russian FederationShabalinaA. A.ШабалинаА. А.Russian FederationKostyrevaM. V.КостыреваМ. В.Russian FederationRudnichenkoV. A.РудниченкоВ. А.Russian FederationGalkinaO. I.ГалкинаО. И.Russian FederationFederal State Budgetary Research Institution “Research Center for Neurology”ФГБНУ «Научный центр неврологии»80 Volokolamskoe Shosse, Moscow, 125367, RussiaРоссия, 125367, Москва, Волоколамское шоссе, 80210920155350612109201521092015Copyright ©; 2015, Shcherbakova N.I., Suponeva N.A., Shvedkov V.V., Shabalina A.A., Kostyreva M.V., Rudnichenko V.A., Galkina O.I.Copyright ©; 2015, Щербакова Н.И., Супонева Н.А., Шведков В.В., Шабалина А.А., Костырева М.В., Рудниченко В.А., Галкина О.И.2015Shcherbakova N.I., Suponeva N.A., Shvedkov V.V., Shabalina A.A., Kostyreva M.V., Rudnichenko V.A., Galkina O.I.Щербакова Н.И., Супонева Н.А., Шведков В.В., Шабалина А.А., Костырева М.В., Рудниченко В.А., Галкина О.И.https://creativecommons.org/licenses/by/4.0https://nmb.abvpress.ru/jour/article/view/124refractory myastheniarituximabselective B cell targeted therapyB-cell depletion (CD20)variations of autoantibodies to acetylcholine receptor (AChR) levelsAChR positive myasthenia gravisQMG ScoreMGFA clinical classificationрефрактерная миастенияритуксимабселективная В-клеточная таргетная терапияистощение В-лимфо- цитов (CD20)изменения уровня антител к ацетилхолиновым рецепторам (АХР)АХР-позитивная миастенияоценочная шкала злокачественной миастении (QMG Score)[1. Sieb J.P. Myasthenia gravis: an update for the clinician. Clin Exp Immunol 2014;175(3):408–18.Sieb J.P. Myasthenia gravis: an update for the clinician. Clin Exp Immunol 2014;175(3):408–18.][2. Щербакова Н.И., Разумовский А.Ю., Митупов З.Б. и др. Особенности детской миастении с антителами к специфической мышечной тирозинкиназе. Неврологический журнал 2014;19(6):36–43. [Shcherbakova N.I., Razumovskiy A.Yu., Mitupov Z.B. et al. Peculiarities of children's myasthenia with antibodies to specific muscle tyrosine kinase. Nevrologicheskiy zhurnal = Neurological Journal 2014;19(6):36–43. (In Russ.)].Щербакова Н.И., Разумовский А.Ю., Митупов З.Б. и др. Особенности детской миастении с антителами к специфической мышечной тирозинкиназе. Неврологический журнал 2014;19(6):36–43. [Shcherbakova N.I., Razumovskiy A.Yu., Mitupov Z.B. et al. Peculiarities of children's myasthenia with antibodies to specific muscle tyrosine kinase. Nevrologicheskiy zhurnal = Neurological Journal 2014;19(6):36–43. (In Russ.)].][3. Burden S.J., Yumoto N., Zhang W. The role of MuSK in synapse formation and neuromuscular disease. Cold Spring Harb Perspect Biol 2013;5(5):a009167.Burden S.J., Yumoto N., Zhang W. The role of MuSK in synapse formation and neuromuscular disease. Cold Spring Harb Perspect Biol 2013;5(5):a009167.][4. Yumoto N., Kim N.,Burden S.J. Lrp4 is a retrograde signal for presynaptic differentiation at neuromuscular synapses. Nature 2012;489(7416):438–42.Yumoto N., Kim N.,Burden S.J. Lrp4 is a retrograde signal for presynaptic differentiation at neuromuscular synapses. Nature 2012;489(7416):438–42.][5. Zhang B., Tzartos J.S., Belimezi M. et al. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol 2012;69(4):445–51.Zhang B., Tzartos J.S., Belimezi M. et al. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol 2012;69(4):445–51.][6. Кузин М.И., Гехт Б.М. Миастения. М.: Медицина, 1996. 224 с. [Kuzin M.I., Gecht B.M. Myasthenia. Moscow, Medicine, 1996. 224 p. (In Russ.)].Кузин М.И., Гехт Б.М. Миастения. М.: Медицина, 1996. 224 с. [Kuzin M.I., Gecht B.M. Myasthenia. Moscow, Medicine, 1996. 224 p. (In Russ.)].][7. Zebardast N., Patwa H.S., Novella S.P., Goldstein J.M. Rituximab in the management of refractory myasthenia gravis. Muscle Nerve 2010;41(3):375–8.Zebardast N., Patwa H.S., Novella S.P., Goldstein J.M. Rituximab in the management of refractory myasthenia gravis. Muscle Nerve 2010;41(3):375–8.][8. Townsend M.J., Monroe J.G., Chan A.C. B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunol Rev 2010;237:264–83.Townsend M.J., Monroe J.G., Chan A.C. B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunol Rev 2010;237:264–83.][9. Lisak R.P., Ragheb S. The role of B cellactivating factor in autoimmune myasthenia gravis. Ann NY Acad Sci 2012;1274:60–7.Lisak R.P., Ragheb S. The role of B cellactivating factor in autoimmune myasthenia gravis. Ann NY Acad Sci 2012;1274:60–7.][10. Keung B., Robeson K.R., DiCapua D.B. et al. Long-term benefit of rituximab in MuSK autoantibody myasthenia gravis patients. J Neurol Neurosurg Psychiatry 2013;84(12):1407–9.Keung B., Robeson K.R., DiCapua D.B. et al. Long-term benefit of rituximab in MuSK autoantibody myasthenia gravis patients. J Neurol Neurosurg Psychiatry 2013;84(12):1407–9.][11. Barohn R.J., McIntire D., Herbelin L. et al. Reliability testing of the quantitative myasthenia gravis score. Ann NY Acad Sci 1998;841:769–72.Barohn R.J., McIntire D., Herbelin L. et al. Reliability testing of the quantitative myasthenia gravis score. Ann NY Acad Sci 1998;841:769–72.][12. Bedlack R.S., Simel D.L., Bosworth H. et al. Quantitative myasthenia gravis score: assessment of responsiveness and longitudinal validity. Neurology 2005;64(11):1968–70.Bedlack R.S., Simel D.L., Bosworth H. et al. Quantitative myasthenia gravis score: assessment of responsiveness and longitudinal validity. Neurology 2005;64(11):1968–70.][13. Пирадов М.А., Супонева Н.А. Синдром Гийена–Барре: диагностика и лечение. М.: МЕДпресс-информ, 2011. 208 с.Пирадов М.А., Супонева Н.А. Синдром Гийена–Барре: диагностика и лечение. М.: МЕДпресс-информ, 2011. 208 с.][[Piradov M.A., Suponeva N.A. Guillain–Barre Syndrome: Diagnostics and Treatment. Moscow: MEDpress-Inform, 2011. 208 p. (In Russ.)].][14. Marinos C. Dalakas. B cells as therapeutic targets in autoimmune neurological disorders. Nat Clin Pract Neurol 2008;10:4.Marinos C. Dalakas. B cells as therapeutic targets in autoimmune neurological disorders. Nat Clin Pract Neurol 2008;10:4.][15. Mixalis L. Kosmidis, Marinos C. Dalakas. Practical considerations on the use of rituximab in autoimmune neurological diseases. Ther Adv Neurol Disord 2010; 3(2):93–105.Mixalis L. Kosmidis, Marinos C. Dalakas. Practical considerations on the use of rituximab in autoimmune neurological diseases. Ther Adv Neurol Disord 2010; 3(2):93–105.][16. Гришина Д.А., Супонева Н.А., Пирадов М.А. Синдром Гийена–Барре: особенности восстановления демиелинизирующих и аксональных форм. Анналы клинической и экспериментальной неврологии 2012;6(4):18–25. [Grishina D.A., Suponeva N.A., Piradov M.A. Guillain–Barre Syndrome: Peculiarities of recovery from demyelination and axonal forms. Annaly klinicheskoy i experimentalnoy nevrologii = Annals of Clinical and Experimental Neurology 2012;6(4):18–25. (In Russ.)].Гришина Д.А., Супонева Н.А., Пирадов М.А. Синдром Гийена–Барре: особенности восстановления демиелинизирующих и аксональных форм. Анналы клинической и экспериментальной неврологии 2012;6(4):18–25. [Grishina D.A., Suponeva N.A., Piradov M.A. Guillain–Barre Syndrome: Peculiarities of recovery from demyelination and axonal forms. Annaly klinicheskoy i experimentalnoy nevrologii = Annals of Clinical and Experimental Neurology 2012;6(4):18–25. (In Russ.)].][17. Hain B., Jordan K., Deschauer M., Zierz S. Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab. Muscle Nerve 2006;33(4):575–80.Hain B., Jordan K., Deschauer M., Zierz S. Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab. Muscle Nerve 2006;33(4):575–80.][18. Illa I., Diaz-Manera J., Rojas-Garcia R. et al. Sustained response to Rituximab in anti- AChR and anti-MuSK positive myasthenia gravis patients. J Neuroimmunol 2008;201– 202:90–4.Illa I., Diaz-Manera J., Rojas-Garcia R. et al. Sustained response to Rituximab in anti- AChR and anti-MuSK positive myasthenia gravis patients. J Neuroimmunol 2008;201– 202:90–4.][19. Burusnukul P., Brennan T.D., Cupler E.J. Prolonged improvement after rituximab: two cases of resistant muscle-specific receptor tyrosine kinase + myasthenia gravis. J Clin Neuromuscul Dis 2010;12(2):85–7.Burusnukul P., Brennan T.D., Cupler E.J. Prolonged improvement after rituximab: two cases of resistant muscle-specific receptor tyrosine kinase + myasthenia gravis. J Clin Neuromuscul Dis 2010;12(2):85–7.][20. Lindberg C., Bokarewa M. Rituximabfor severe myasthenia gravis--experience from five patients. Acta Neurol Scand 2010;122(4);225–8.Lindberg C., Bokarewa M. Rituximabfor severe myasthenia gravis--experience from five patients. Acta Neurol Scand 2010;122(4);225–8.][21. Koul R., Al Futaisi A., Abdwani R. Rituximab in severe seronegative juvenile myasthenia gravis: review of the literature. Pediatr Neurol 2012;47(3):209–12.Koul R., Al Futaisi A., Abdwani R. Rituximab in severe seronegative juvenile myasthenia gravis: review of the literature. Pediatr Neurol 2012;47(3):209–12.][22. Wylam M.E., Anderson P.M., Kuntz N.L., Rodriguez V. Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report. J Pediatr 2003;143(5):674–7.Wylam M.E., Anderson P.M., Kuntz N.L., Rodriguez V. Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report. J Pediatr 2003;143(5):674–7.][23. Maddison P., McConville J., Farrugia M.E. et al. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 2011;82(6):671–3.Maddison P., McConville J., Farrugia M.E. et al. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 2011;82(6):671–3.][24. Iorio R., Damato V., Alboini P.E. Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis. J Neurol 2014 Oct 12.Iorio R., Damato V., Alboini P.E. Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis. J Neurol 2014 Oct 12.][25. Насонов Е.Л. Материалы совещания экспертов по регистру пациентов с ревматоидным артритом, получающих ритуксимаб (Мабтеру). Научно-практическая ревматология 2008;1. Приложение 3–10. [Nasonov E.L. Materials of consultation of experts for the register of patients with rheumatoid arthritis that receive rituximab (Mabtera). Nauchno-prakticheskaya revmatologiya = Scientific and Practical Rheumatology 2008;1. Appendix: 3–10. (In Russ.)].Насонов Е.Л. Материалы совещания экспертов по регистру пациентов с ревматоидным артритом, получающих ритуксимаб (Мабтеру). Научно-практическая ревматология 2008;1. Приложение 3–10. [Nasonov E.L. Materials of consultation of experts for the register of patients with rheumatoid arthritis that receive rituximab (Mabtera). Nauchno-prakticheskaya revmatologiya = Scientific and Practical Rheumatology 2008;1. Appendix: 3–10. (In Russ.)].]